Table 2.

Characteristics of the studies on miR-141 included in this meta-analysis.

Author	Publication year	Origin of population	Number of cases	Cancer type	Sample	Test method	Cut-off	Survival analysis	Estimated HR	Prognosis
Cheng et al. [37]	2011	America; China	102; 156	Colorectal cancer	Plasma	qRT-PCR	Median	OS	Reported	Negative
Diaz et al. [26]	2014	Spain	56	Colorectal cancer	Tissue	qRT-PCR	NA	OS; PFS	Estimated	Positive
Liu et al. [38]	2014	China	212	Hepatocellular carcinoma	Tissue	ISH	An SI score of 3	OS	Reported	Positive
Tejero et al. [31]	2014	Spain	70; 72	Lung cancer	Tissue	qRT-PCR	NA	OS	Estimated	Negative
Selth et al. [39]	2013	Australia	70	Prostate cancer	Serum	qRT-PCR	Median	EFS	Reported	Positive
Liu et al. [32]	2012	China	70	Lung cancer	Tissue	qRT-PCR	2-fold	OS	Reported	Negative
Marchini et al. [40]	2013	Italy	52	Ovarian cancer	Tissue	qRT-PCR	25th quartiles	OS; PFS	Reported	Negative
Zhao et al. [41]	2013	China	40	Pancreatic cancer	Tissue	qRT-PCR	Median	OS	Estimated	Positive
Ratert et al. [19]	2013	Germany	40	Bladder cancer	Tissue	qRT-PCR	Median	OS	Estimated	Positive
Silva-Santos et al. [42]	2013	Portugal	90	Renal cancer	Tissue	qRT-PCR	Median	DSS	Estimated	Positive

qRT-PCR: quantitative real-time polymerase chain reaction; ISH: in situ hybridization; NA: not available; SI (staining index score): staining intensity × proportion of positively stained cells; OS: overall survival; DFS: disease-free survival; PFS: progression-free survival; DSS: disease-specific survival.